China Urged to Abandon Plan to Sell Unproven Cell Therapies
June 7, 2019
(Nature) – An international group of stem-cell researchers is urging China to cancel draft regulations that would permit some hospitals to sell therapies developed from patients’ own cells, without approval from the nation’s drug regulator. The International Society for Stem Cell Research (ISSCR) sent a statement outlining its concerns to Jiao Hong, director of China’s National Medical Products Administration in Beijing, on 20 May. The society, which is based in Skokie, Illinois, represents more than 4,000 scientists, clinicians and ethicists around the world.